Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01915693
Other study ID # WCTU030
Secondary ID 10/50/49
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2013
Est. completion date November 2018

Study information

Verified date June 2019
Source Velindre NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The single most distressing symptom for more than 70% of patients with oesophageal cancer is difficulty in swallowing (dysphagia) caused by blockage of the gullet by a tumour. This causes severe restrictions on food intake, physical activity, social functioning and overall quality of life. Amongst the more effective treatments for improving swallowing, is the insertion of a metal stent across the blocked part, which then self-expands to open up the gullet (Self Expanding Metal Stent or SEMS). The addition of radiotherapy may help to improve the problems caused by dysphagia and provide an additional survival benefit.

The purpose of this study is to test the impact of adding radiotherapy to SEMS on:

- the length of time swallow remains improved for

- quality of life

- survival


Description:

The primary objective of the study is to assess the impact of radiotherapy in addition to self-expanding metal stent (SEMS) placement on time to progression of patient-reported dysphagia in a patient population unable to undergo surgery.

Patients will be eligible to take part in the trial if they have oesophageal cancer, are in need of SEMS because of dysphagia, are aged 16 years or older, have been clinically assessed to be able to receive radiotherapy, have an expected survival of at least 12 weeks and are able to give written informed consent.

496 patients will be randomised to receive either SEMS alone or SEMS with radiotherapy. The radiotherapy will be given as an outpatient either as five treatments (one per day) over one week, or ten treatments over two weeks. Questionnaires will be completed before treatment, and at weeks two and four and then monthly for up to one year to assess quality of life and cost effectiveness. Interviews will be held with trial participants at three time points to explore their experiences while on the trial. Interviews will also be held with patients who do not consent to take part in the trial to explore their reasons for non-consent.

Treatments:

Arm A: Self-expanding metal stents (SEMS) (Control Arm) SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.

Arm B: SEMS plus external beam radiotherapy (Intervention Arm) External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.

There will also be a qualitative component of the trial will have two aims: i) to explore the feasibility of patients' recruitment to the trial and ii) to explore participants' experience of the trial interventions. It will examine their experience of consent and recruitment including reasons for declining, and examine patients' motivation to accept randomisation to an intervention which may include extra radiotherapy. This is an optional component and will require separate consent. Patients who do not consent to the trial, but who do consent to the qualitative component, will be interviewed about their reasons for not-consenting as soon as possible after the approach to participate.

Trial participants who consent to the qualitative component will be interviewed three times: at weeks one and four to capture initial decision-making thoughts and then after the interventions (week 8) to explore patients' experience of interventions and perceptions of benefit or detriment.


Recruitment information / eligibility

Status Completed
Enrollment 220
Est. completion date November 2018
Est. primary completion date November 2018
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria:

1. Histological confirmation of oesophageal carcinoma excluding small cell histology

2. Not suitable for radical treatment (oesophagectomy or radical chemoradiotherapy) either because of patient choice or medical reasons

3. Dysphagia clinically assessed as needing stent as primary treatment of the dysphagia

4. Age 16 years or over

5. Discussion and treatment decision for stent placement made by an upper GI multi-disciplinary team

6. Clinician assessment of ability to attend for radiotherapy

7. Expected survival of at least 12 weeks

8. Written informed consent

9. Patient has completed baseline Quality of Life Questionnaires (please note, as a minimum patients must have completed OG25)

Exclusion Criteria:

1. Histology of small cell carcinoma type

2. Tumour length of greater than 12 cm

3. Tumour growth within 2 cm of the upper oesophageal sphincter

4. Endoscopic treatment of the tumour, other than dilatation, planned in the peri-stent period

5. Presence of a tracheo-oesophageal fistula

6. Presence of a pacemaker in proposed radiotherapy field

7. Previous radiotherapy to the area of the proposed radiotherapy field

8. Planned endoscopic treatment of the tumour (e.g. laser) in the immediate peri-stenting period

9. Female patient who is pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Radiotherapy
External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.

Locations

Country Name City State
United Kingdom Ysbyty Gwynedd Bangor Wales
United Kingdom Bristol Haematology and Oncology Centre Bristol England
United Kingdom Velindre Cancer Center at Velindre Hospital Cardiff Wales
United Kingdom Doncaster Royal Infirmary Doncaster England
United Kingdom Ninewells Hospital Dundee Scotland
United Kingdom James Cook University Hospital Middlesbrough England
United Kingdom Royal Gwent Hospital Newport Gwent Wales
United Kingdom George Eliot Hospital Nuneaton England
United Kingdom Glan Clwyd Hospital Rhyl, Denbighshire Wales
United Kingdom Conquest Hospital Saint Leonards-on-Sea England
United Kingdom Cancer Research Centre at Weston Park Hospital Sheffield England
United Kingdom Weston Park Hospital Sheffield
United Kingdom Southampton General Hospital Southampton
United Kingdom Musgrove Park Hospital Taunton England
United Kingdom Southend University Hospital NHS Foundation Trust Westcliff-On-Sea England
United Kingdom Weston General Hospital Weston-super-Mare England
United Kingdom Wrexham Maelor Hospital Wrexham Wales

Sponsors (1)

Lead Sponsor Collaborator
Lisette Nixon

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary patient-reported dysphagia Assess the impact of radiotherapy in addition to self-expanding metal stent (SEMS) placement on time to progression of patient-reported dysphagia in a patient population unable to undergo surgery. within one year
Secondary quality of life Assess the impact of combination treatment on core components of health related quality of life within one year
Secondary overall survival Assess the impact of radiotherapy in addition to SEMS placement on overall survival one year
Secondary morbidity Measure morbidity associated with the interventions one year
Secondary re-intervention rate Measure re-intervention rates one year
Secondary cost Assess the cost of the addition of radiotherapy to SEMS placement one year
See also
  Status Clinical Trial Phase
Recruiting NCT05685862 - Laser Speckle Contrast Imaging, Surgical Eye & ICG Fluorescence Imaging for Perfusion Assessment of the Gastric Conduit
Recruiting NCT01795768 - Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours Phase 2
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Recruiting NCT03978377 - Cardiopulmonary Toxicity of Thoracic Radiotherapy
Active, not recruiting NCT03653052 - Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab Phase 2
Recruiting NCT05489250 - The PLATON Network
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Terminated NCT01795976 - NY-ESO-1 T Cells in OG Cancer Phase 2
Recruiting NCT01843829 - A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer Phase 2
Completed NCT02382237 - Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition N/A
Recruiting NCT04517448 - Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy
Recruiting NCT04232735 - Evidence Based Information Provision to Improve Decision Making After Oesophagogastric Cancer Diagnosis (SOURCE) N/A
Recruiting NCT05642819 - REVOLUTION Surgery (REVOLUTION Surgery)
Recruiting NCT04001478 - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Recruiting NCT02741856 - Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Phase 2/Phase 3
Not yet recruiting NCT05600608 - Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome N/A
Recruiting NCT04481256 - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY N/A
Recruiting NCT05057013 - HMBD-001 in Advanced HER3 Positive Solid Tumours Phase 1/Phase 2
Not yet recruiting NCT06046846 - Prehabilitation Via a Mobile Application in Oesophago-gastric Cancer N/A
Recruiting NCT04564482 - PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer N/A